Patients with intrahepatic cholangiocarcinoma (ICC), a form of bile duct cancer, have a poor prognosis. Researchers at Tokyo Medical and Dental University (TMDU) identified a protein called ARID1A that contributes to poor outcomes in ICC. Loss of ARID1A enhances the malignancy of ICC tumor cells and can predict worse survival outcomes. The findings could eventually form the basis of a prognostic biomarker for ICC and new treatment options for ARID1A-negative patients.
- Ministry of Education, Culture, Sports, Science and Technology,JAPAN, Japan Agency for Medical Research and Development, Princess Takamatsu Cancer Research Fund